Gerasimos Baltayiannis

Gerasimos Baltayiannis

Auto-generated profile, based on publicly available information

Gerasimos Baltayiannis

Division of Gastroenterology, Medical School, University of Ioannina, Ioannina, Greece

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Journal of Hepatology
Verified
Journal Article
Closed access
GKGeorgios N. Kalambokis
Georgios N. Kalambokis
AOAikaterini Oikonomou
Aikaterini Oikonomou
LCLeonidas Christou
Leonidas Christou
NKNikolaos I. Kolaitis
Nikolaos I. Kolaitis
ETEpameinondas V. Tsianos
Epameinondas V. Tsianos
GBGerasimos Baltayiannis
Gerasimos Baltayiannis

1 May 2001 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
ABA. Bamias
A. Bamias
GBG. Baltayiannis
G. Baltayiannis
SKS. Kamina
S. Kamina
MFM. Fatouros
M. Fatouros
ELE. Lymperopoulos
E. Lymperopoulos
NPN. Pavlidis
N. Pavlidis
Metastatic involvement of the gastrointestinal (GI) tract secondary to breast cancer is rare. Reported herein is the case of a 74-year-old woman with

3 April 2019 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
FFFotios S. Fousekis
Fotios S. Fousekis
KKKonstantinos H. Katsanos
Konstantinos H. Katsanos
VTVasileios I. Theopistos
Vasileios I. Theopistos
GBGerasimos Baltayiannis
Gerasimos Baltayiannis
MKMaria Kosmidou
Maria Kosmidou
DCDimitrios K Christodoulou
Dimitrios K Christodoulou
Hepatobiliary and pancreatic manifestations have been reported in patients with Crohn’s disease or ulcerative colitis. Our aim was to describe the prevalence of hepatobiliary and pancreatic manifestations in inflammatory bowel disease and their association with the disease itself and the medications used. Data were retrospectively extracted from the clinical records of patients followed up at our tertiary IBD referral Center. Our study included 602 IBD patients, with liver function tests at regular intervals. The mean follow-up was 5.8 years (Std. Dev.: 6.72). Abdominal imaging examinations were present in 220 patients and revealed findings from the liver, biliary tract and pancreas in 55% of examined patients (120/220). The most frequent findings or manifestations from the liver, biliary tract and pancreas were fatty liver (20%, 44/220), cholelithiasis (14.5%, 32/220) and acute pancreatitis (0.6%, 4/602), respectively. There were 7 patients with primary sclerosing cholangitis. Regarding hepatitis viruses, one-third of the patients had been tested for hepatitis B and C. 5% (12/225) of them had positive hepatitis B surface antigen and 13.4% had past infection with hepatitis B virus (positive anti-HBcore). In addition, most of the patients were not immune against hepatitis B (negative anti-HBs), while 3% of patients were anti-HCV positive and only one patient had active hepatitis C. Furthermore, 24 patients had drug-related side effects from the liver and pancreas. The side effects included 21 cases of hepatotoxicity and 3 cases of acute pancreatitis. Moreover, there were two cases of HBV reactivation and one case of chronic hepatitis C, which were successfully treated. In our study, approximately one out of four patients had some kind by a hepatobiliary or pancreatic manifestation. Therefore, it is essential to monitor liver function at regular intervals and differential diagnosis should range from benign diseases and various drug related side effects to severe disorders, such as primary sclerosing cholangitis.

26 March 2016 in Hepatology
Verified
Journal Article
Open access
PDF file
GKGeorgios N. Kalambokis
Georgios N. Kalambokis
DCDimitrios Christodoulou
Dimitrios Christodoulou
GBGerasimos Baltayiannis
Gerasimos Baltayiannis
LCLeonidas Christou
Leonidas Christou
Click on the article title to read more.

16 October 2008 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
CZC. D. Zois
C. D. Zois
GBG. H. Baltayiannis
G. H. Baltayiannis
PKPeter Karayiannis
Peter Karayiannis
ETE. V. Tsianos
E. V. Tsianos
Summary: Background  Hepatic fibrosis occurs in response to chronic liver injury, regardless of the cause. An impressive amount of knowledge concerning the pathogenesis and treatment of liver fibrosis has emerged over the past few years. The hallmark of this event is the activation of the hepatic stellate cell. The latter event causes accumulation of extracellular matrix and formation of scar, leading to deterioration in hepatic function.Aim  To assess chronic liver injury, many invasive and non‐invasive methods have been suggested.Methods  Although transient elastography, image analysis of fractal geometry and fibrotest with actitest have been used in clinical practice, liver biopsy remains the recommended choice, especially when histological staging of fibrosis or response to treatment is needed.Conclusions  The recent advances in anti‐viral therapy have resulted in many reports on fibrosis and even on cirrhosis regression, especially early and in young people. A number of new agents have been suggested for the treatment of fibrosis, with promising results in animals; however, their efficacy in humans remains to be elucidated. The investigation of heterogeneity and plasticity of hepatic stellate cells is a topic of scientific interest and may result in improvements in patient management.

3 April 2008 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
MEMichael Economou
Michael Economou
HMHaralampos Milionis
Haralampos Milionis
SFSpyridon Filis
Spyridon Filis
GBGerasimos Baltayiannis
Gerasimos Baltayiannis
LCLeonidas Christou
Leonidas Christou
ETEpameinondas Tsianos
Epameinondas Tsianos